About: Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

clinical trial

Attributes	Values
rdf:type	Item
description	clinical trial (en) ensayu clínicu (ast) klinisch onderzoek (nl) клінічне випробування (uk)
rdfs:label	Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms (en)
skos:prefLabel	Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms (en)
name	Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms (en)
title	wds:Q64676643-318DE1F8-B143-4D42-BE9D-6484ED17A43F
title	A Phase 2, Multicenter Study With Open-label & Randomized Double-blind Placebo-controlled Withdrawal Phases to Evaluate the Efficacy, Safety, & Tolerability of SPD489 in Adults With Schizophrenia & Predominant Negative Symptoms Who Are Clinically Stable & Taking Stable Doses of Atypical Antipsychotic Medication (en)
end time	wds:Q64676643-6D9B725E-2F2C-4666-B0CC-7D4E580ABE8A
end time	2011-01-01 00:00:00Z (xsd:dateTime)
instance of	wds:Q64676643-DEF0612F-B831-4FCF-B855-1B3B4F5DDE3F
instance of	clinical trial
start time	wds:Q64676643-244A1431-35F9-4D49-B89B-35608677ECAF
start time	2009-09-01 00:00:00Z (xsd:dateTime)
country	wds:Q64676643-1A85DDDF-DFEB-4C61-A65A-A0C458AAB030
country	United States of America
research site	wds:Q64676643-23BC7EA7-72B3-46EF-9FD5-348A3ECFFAE4 wds:Q64676643-6B07C3D8-0D73-4379-9F13-F318C2043043 wds:Q64676643-8EA99D66-84FB-4A49-B93E-28530A5793BA
research site	University of Cincinnati Stedman Clinical Trials Community Clinical Research
research intervention	wds:Q64676643-5DDCA980-D420-4E6D-8239-90ADE4913684
research intervention	lisdexamfetamine dimesylate
minimum age	wds:Q64676643-51048C03-B9BF-4151-A8F6-FF0D28667226
minimum age	18 (xsd:decimal)
medical condition	wds:Q64676643-0D1F2B17-F0E3-49A1-866D-09D17000C61A
medical condition	schizophrenia
number of participants	wds:Q64676643-96A473E0-06D6-4494-AC27-758F80E053D8
number of participants	92 (xsd:decimal)
maximum age	wds:Q64676643-2A2B0756-6ACA-43C8-A15D-B628FF7C762D
maximum age	55 (xsd:decimal)
study type	wds:Q64676643-C964B8C4-3021-4BF6-939D-4C5B03DB8878
study type	interventional study
ClinicalTrials.gov ID	wds:Q64676643-73C58345-2930-45AF-AEDE-86DF24C5E049
ClinicalTrials.gov ID	NCT00922272
clinical trial phase	wds:Q64676643-1E9BF57F-BCB8-4753-9EB3-70D2EA0249AB
clinical trial phase	phase II clinical trial
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q64676643

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software